Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

CHEK2*1100delC is not an important high-risk gene in families with hereditary prostate cancer in southern Sweden

Wagenius, M ; Borg, Åke LU ; Johansson, L ; Giwercman, Aleksander LU and Bratt, Ola LU (2006) In Scandinavian Journal of Urology and Nephrology 40(1). p.23-25
Abstract
Objective. CHEK2* 1100delC is a frame-shifting germ-line mutation which abolishes the function of cell-cycle-checkpoint kinase 2 (chk2) and hence impairs the cells' response to DNA damage. This variant occurs in approximate to 1% of the general Western population but has been reported to be more common among patients with breast and prostate cancer. The aim of this study was to investigate the significance of CHEK2* 1100delC as a possible high-risk gene for hereditary prostate cancer in the population of southern Sweden. Material and methods. We screened for the CHEK2* 1100delC variant in 419 men diagnosed with prostate cancer in southern Sweden, 145 of whom were sporadic cases that were divided into two subgroups depending on whether they... (More)
Objective. CHEK2* 1100delC is a frame-shifting germ-line mutation which abolishes the function of cell-cycle-checkpoint kinase 2 (chk2) and hence impairs the cells' response to DNA damage. This variant occurs in approximate to 1% of the general Western population but has been reported to be more common among patients with breast and prostate cancer. The aim of this study was to investigate the significance of CHEK2* 1100delC as a possible high-risk gene for hereditary prostate cancer in the population of southern Sweden. Material and methods. We screened for the CHEK2* 1100delC variant in 419 men diagnosed with prostate cancer in southern Sweden, 145 of whom were sporadic cases that were divided into two subgroups depending on whether they were diagnosed before ( n = 64) or after ( n = 81) the age of 55 years. A further 126 men were classified as familial prostate cancer cases and 148 as hereditary prostate cancer cases. The control group consisted of 305 military conscripts aged approximate to 18 years ( range 18 - 21 years). Results. The CHEK2* 1100delC variant was found in 1.2% of the cases ( sporadic: 0.7%; familial: 1.6%; hereditary: 1.4%) and in 1.0% of the controls. Conclusion. The CHEK2 1100delC mutation is not a clinically important high-risk gene for hereditary prostate cancer susceptibility in the population of southern Sweden. (Less)
Please use this url to cite or link to this publication:
author
; ; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
cell-cycle-checkpoint kinase 2, genetics, germ-line mutation, risk factors, prostatic neoplasms, CHEK2
in
Scandinavian Journal of Urology and Nephrology
volume
40
issue
1
pages
23 - 25
publisher
Taylor & Francis
external identifiers
  • wos:000235475100003
  • pmid:16452051
  • scopus:32144449216
  • pmid:16452051
ISSN
0036-5599
DOI
10.1080/00365590500368518
language
English
LU publication?
yes
id
f39ad301-187d-4e5e-ae7e-8357a713e630 (old id 417339)
date added to LUP
2016-04-01 16:02:56
date last changed
2021-03-24 05:39:10
@article{f39ad301-187d-4e5e-ae7e-8357a713e630,
  abstract     = {Objective. CHEK2* 1100delC is a frame-shifting germ-line mutation which abolishes the function of cell-cycle-checkpoint kinase 2 (chk2) and hence impairs the cells' response to DNA damage. This variant occurs in approximate to 1% of the general Western population but has been reported to be more common among patients with breast and prostate cancer. The aim of this study was to investigate the significance of CHEK2* 1100delC as a possible high-risk gene for hereditary prostate cancer in the population of southern Sweden. Material and methods. We screened for the CHEK2* 1100delC variant in 419 men diagnosed with prostate cancer in southern Sweden, 145 of whom were sporadic cases that were divided into two subgroups depending on whether they were diagnosed before ( n = 64) or after ( n = 81) the age of 55 years. A further 126 men were classified as familial prostate cancer cases and 148 as hereditary prostate cancer cases. The control group consisted of 305 military conscripts aged approximate to 18 years ( range 18 - 21 years). Results. The CHEK2* 1100delC variant was found in 1.2% of the cases ( sporadic: 0.7%; familial: 1.6%; hereditary: 1.4%) and in 1.0% of the controls. Conclusion. The CHEK2 1100delC mutation is not a clinically important high-risk gene for hereditary prostate cancer susceptibility in the population of southern Sweden.},
  author       = {Wagenius, M and Borg, Åke and Johansson, L and Giwercman, Aleksander and Bratt, Ola},
  issn         = {0036-5599},
  language     = {eng},
  number       = {1},
  pages        = {23--25},
  publisher    = {Taylor & Francis},
  series       = {Scandinavian Journal of Urology and Nephrology},
  title        = {CHEK2*1100delC is not an important high-risk gene in families with hereditary prostate cancer in southern Sweden},
  url          = {http://dx.doi.org/10.1080/00365590500368518},
  doi          = {10.1080/00365590500368518},
  volume       = {40},
  year         = {2006},
}